Details of the Drug

General Information of Drug (ID: DMHZJCG)

Drug Name
Pentamidine
Synonyms
Lomidine; Nebupent; PENTAM; PNT; Pentacarinat; Pentamide; Pentamidin; Pentamidina; Pentamidinum; Pneumopent; PENTAMIDINE ISETHIONATE; Pentamidina [DCIT]; Pentamidine isetionate; Pentamidine mesylate; MB 800; Pentam 300; Lomidine (TN); MB-800; Nebupent (as isethionate); Pentacarinat (as isethionate); Pentam 300 (as isethionate); Pentamidine (INN); Pentamidinum [INN-Latin]; RP-2512; Nebupent (*Isethionate); Pentacarinat (*Isethionate); Pentam 300 (*Isethionate); Pentamidine Isethionate 2-Hydroxy-Ethanesulfonic Acid;Pentamidine [INN:BAN:DCF]; RP 2512 (*Isethionate); P,p'-(Pentamethylenedioxy)bis[benzamidine]; P,p'-(Pentamethylenedioxy)dibenzamidine; P,p'-(Pentamethylene-dioxy)bis-benzamidine; Benzenecarboximidamide, 4,4'-(1,5-pentanediylbis(oxy))bis-(9CI); 1,3-BIS(4-AMIDINOPHENOXY)PENTANE; 4, 4'-Diamidinodiphenoxypentane; 4,4'-(1,5-Pentanediylbis(oxy))bis-benzenecarboximidamide; 4,4'-(Pentamethylenedioxy)dibenzamide; 4,4'-(Pentamethylenedioxy)dibenzamidine; 4,4'-Diamidino-.alpha.,.omega.-diphenoxypentane; 4,4'-Diamidinodiphenoxypentane; 4,4'-[pentane-1,5-diylbis(oxy)]dibenzenecarboximidamide; 4-[5-(4-Carbamimidoylphenoxy)pentoxy]benzenecarboximidamide
Indication
Disease Entry ICD 11 Status REF
Fungal infection 1F29-1F2F Approved [1]
Human immunodeficiency virus infection 1C62 Withdrawn from market [2]
Therapeutic Class
Antifungal Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 340.4
Topological Polar Surface Area (xlogp) 2.6
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption
The drug is poorly absorbed from the gastrointestinal tract [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 74 mL/min/kg [5]
Elimination
12% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 9.1 - 13.2 hours [5]
Metabolism
The drug is metabolized via the hepatic [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 11.74989 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.09% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 53 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 100 mg/mL [4]
Chemical Identifiers
Formula
C19H24N4O2
IUPAC Name
4-[5-(4-carbamimidoylphenoxy)pentoxy]benzenecarboximidamide
Canonical SMILES
C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N
InChI
InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)
InChIKey
XDRYMKDFEDOLFX-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4735
ChEBI ID
CHEBI:45081
CAS Number
100-33-4
DrugBank ID
DB00738
TTD ID
D05EAM
VARIDT ID
DR00085
INTEDE ID
DR1252

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tryptase alpha/beta-1 (Tryptase) TTM1TDX TRYB1_HUMAN Inhibitor [7], [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [10]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [11]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [10]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Fungal infection
ICD Disease Classification 1F29-1F2F
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tryptase alpha/beta-1 (Tryptase) DTT TPSAB1 3.09E-07 1.07 0.89
Organic cation transporter 1 (SLC22A1) DTP SLC22A1 8.27E-06 1.93E-01 5.03E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 2.93E-03 -2.19E-01 -4.49E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 7.57E-07 -1.95E-01 -4.24E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 3.85E-05 8.08E-01 6.07E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 1.65E-02 -4.37E-02 -7.84E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 1.21E-04 -2.33E-01 -5.09E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 6.90E-01 2.35E-02 7.88E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Pentamidine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Ketoconazole. Fungal infection [1F29-1F2F] [78]
Coadministration of a Drug Treating the Disease Different from Pentamidine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Pentamidine and Ivosidenib. Acute myeloid leukaemia [2A60] [79]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Midostaurin. Acute myeloid leukaemia [2A60] [78]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Idarubicin. Acute myeloid leukaemia [2A60] [78]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Arn-509. Acute myeloid leukaemia [2A60] [80]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Gilteritinib. Acute myeloid leukaemia [2A60] [81]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Oliceridine. Acute pain [MG31] [78]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Rivastigmine. Alzheimer disease [8A20] [78]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Donepezil. Alzheimer disease [8A20] [78]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Pentamidine and Metronidazole. Amoebiasis [1A36] [82]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Pentamidine and Ivabradine. Angina pectoris [BA40] [80]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Pentamidine and Bepridil. Angina pectoris [BA40] [78]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Pentamidine and Dronedarone. Angina pectoris [BA40] [78]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Pentamidine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [83]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Cilostazol. Arterial occlusive disease [BD40] [78]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Posaconazole. Aspergillosis [1F20] [78]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Levalbuterol. Asthma [CA23] [84]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Terbutaline. Asthma [CA23] [85]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Pirbuterol. Asthma [CA23] [85]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Salbutamol. Asthma [CA23] [84]
Formoterol DMSOURV Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Formoterol. Asthma [CA23] [85]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Desipramine. Attention deficit hyperactivity disorder [6A05] [78]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Ofloxacin. Bacterial infection [1A00-1C4Z] [86]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Clarithromycin. Bacterial infection [1A00-1C4Z] [78]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Pentamidine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [78]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Pentamidine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [86]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [86]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Norfloxacin. Bacterial infection [1A00-1C4Z] [86]
Rabeprazole DMMZXIW Moderate Increased risk of hypomagnesemia by the combination of Pentamidine and Rabeprazole. Bacterial infection [1A00-1C4Z] [87]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Levofloxacin. Bacterial infection [1A00-1C4Z] [86]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [78]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Telithromycin. Bacterial infection [1A00-1C4Z] [78]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Retigabine. Behcet disease [4A62] [78]
Etidronic acid DM1XHYJ Moderate Increased risk of nephrotoxicity by the combination of Pentamidine and Etidronic acid. Bone paget disease [FB85] [88]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Loperamide. Bowel habit change [ME05] [89]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Eribulin. Breast cancer [2C60-2C6Y] [78]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Lapatinib. Breast cancer [2C60-2C6Y] [78]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Bosutinib. Breast cancer [2C60-2C6Y] [80]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Pentamidine and Iodipamide. Cholelithiasis [DC11] [90]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [91]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [85]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [84]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [85]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [85]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [85]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Isoproterenol. Conduction disorder [BC63] [84]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Halothane. Corneal disease [9A76-9A78] [78]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Propofol. Corneal disease [9A76-9A78] [92]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Sevoflurane. Corneal disease [9A76-9A78] [78]
Methoxyflurane DML0RAE Moderate Increased risk of nephrotoxicity by the combination of Pentamidine and Methoxyflurane. Corneal disease [9A76-9A78] [80]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Probucol. Coronary atherosclerosis [BA80] [78]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Clofazimine. Crohn disease [DD70] [93]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Pentamidine and Mifepristone. Cushing syndrome [5A70] [78]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Pentamidine and Pasireotide. Cushing syndrome [5A70] [78]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Osilodrostat. Cushing syndrome [5A70] [80]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Sertraline. Depression [6A70-6A7Z] [78]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Pentamidine and Escitalopram. Depression [6A70-6A7Z] [78]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Clomipramine. Depression [6A70-6A7Z] [78]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Doxepin. Depression [6A70-6A7Z] [78]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Maprotiline. Depression [6A70-6A7Z] [78]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [78]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Deutetrabenazine. Dystonic disorder [8A02] [94]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Ingrezza. Dystonic disorder [8A02] [95]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Solifenacin. Functional bladder disorder [GC50] [78]
Dexlansoprazole DM1DBV5 Moderate Increased risk of hypomagnesemia by the combination of Pentamidine and Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [87]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [78]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [96]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Pentamidine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [97]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [78]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [78]
Etelcalcetide DMHP9BL Major Increased risk of hypocalcemia by the combination of Pentamidine and Etelcalcetide. Hyper-parathyroidism [5A51] [80]
Givosiran DM5PFIJ Moderate Increased risk of nephrotoxicity by the combination of Pentamidine and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [82]
Balsalazide DMO091F Moderate Increased risk of nephrotoxicity by the combination of Pentamidine and Balsalazide. Indeterminate colitis [DD72] [98]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Polyethylene glycol. Irritable bowel syndrome [DD91] [80]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Phenolphthalein. Irritable bowel syndrome [DD91] [78]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Pentamidine and Crizotinib. Lung cancer [2C25] [99]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Pentamidine and Ceritinib. Lung cancer [2C25] [78]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Pentamidine and Osimertinib. Lung cancer [2C25] [100]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Pentamidine and Selpercatinib. Lung cancer [2C25] [80]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Pentamidine and Lumefantrine. Malaria [1F40-1F45] [82]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Pentamidine and Halofantrine. Malaria [1F40-1F45] [101]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Pentamidine and Hydroxychloroquine. Malaria [1F40-1F45] [102]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Primaquine. Malaria [1F40-1F45] [78]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [80]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Pentamidine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [103]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Pentamidine and Vemurafenib. Melanoma [2C30] [78]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and LGX818. Melanoma [2C30] [104]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Pentamidine and Exjade. Mineral absorption/transport disorder [5C64] [105]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Pentamidine and Panobinostat. Multiple myeloma [2A83] [106]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Thalidomide. Multiple myeloma [2A83] [82]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Pentamidine and Siponimod. Multiple sclerosis [8A40] [82]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Pentamidine and Fingolimod. Multiple sclerosis [8A40] [78]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Pentamidine and Ocrelizumab. Multiple sclerosis [8A40] [107]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Pentamidine and Ozanimod. Multiple sclerosis [8A40] [108]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Romidepsin. Mycosis fungoides [2B01] [78]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Pentamidine and Nilotinib. Myeloproliferative neoplasm [2A20] [78]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Dasatinib. Myeloproliferative neoplasm [2A20] [109]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Promethazine. Nausea/vomiting [MD90] [78]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Granisetron. Nausea/vomiting [MD90] [78]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Pentamidine and Dolasetron. Nausea/vomiting [MD90] [78]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Ondansetron. Nausea/vomiting [MD90] [78]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Entrectinib. Non-small cell lung cancer [2C25] [82]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Pentamidine and Levomethadyl Acetate. Opioid use disorder [6C43] [80]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Lofexidine. Opioid use disorder [6C43] [78]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Rucaparib. Ovarian cancer [2C73] [78]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Buprenorphine. Pain [MG30-MG3Z] [78]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Triclabendazole. Parasitic worm infestation [1F90] [78]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Pimavanserin. Parkinsonism [8A00] [110]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Famotidine. Peptic ulcer [DA61] [82]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Pentamidine and Macimorelin. Pituitary gland disorder [5A60-5A61] [111]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Pentamidine and Lefamulin. Pneumonia [CA40] [112]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Ritodrine. Preterm labour/delivery [JB00] [85]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Degarelix. Prostate cancer [2C82] [80]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Pentamidine and ABIRATERONE. Prostate cancer [2C82] [80]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Enzalutamide. Prostate cancer [2C82] [80]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Relugolix. Prostate cancer [2C82] [80]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Bicalutamide. Prostate cancer [2C82] [80]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Levomepromazine. Psychotic disorder [6A20-6A25] [78]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Pentamidine and Everolimus. Renal cell carcinoma [2C90] [113]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Pentamidine and Temsirolimus. Renal cell carcinoma [2C90] [113]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Pentamidine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [114]
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Pentamidine and Sulfasalazine. Rheumatoid arthritis [FA20] [98]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Quetiapine. Schizophrenia [6A20] [78]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Pentamidine and Mesoridazine. Schizophrenia [6A20] [78]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Aripiprazole. Schizophrenia [6A20] [82]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Pentamidine and Iloperidone. Schizophrenia [6A20] [78]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Paliperidone. Schizophrenia [6A20] [78]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Perphenazine. Schizophrenia [6A20] [78]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Trifluoperazine. Schizophrenia [6A20] [78]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Pentamidine and Amisulpride. Schizophrenia [6A20] [82]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Asenapine. Schizophrenia [6A20] [78]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Pentamidine and Pimozide. Schizophrenia [6A20] [80]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Vardenafil. Sexual dysfunction [HA00-HA01] [78]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Pentamidine and LEE011. Solid tumour/cancer [2A00-2F9Z] [78]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Pentamidine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [78]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [80]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [78]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Pitolisant. Somnolence [MG42] [78]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [78]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Lenvatinib. Thyroid cancer [2D10] [78]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Pentamidine and Cabozantinib. Thyroid cancer [2D10] [80]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Pentamidine and Papaverine. Tonus and reflex abnormality [MB47] [115]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Pentamidine and Sirolimus. Transplant rejection [NE84] [113]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Pentamidine and Tacrolimus. Transplant rejection [NE84] [113]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Pentamidine and Olsalazine. Ulcerative colitis [DD71] [98]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Pentamidine and Plazomicin. Urinary tract infection [GC08] [82]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [116]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Pentamidine and Procainamide. Ventricular tachyarrhythmia [BC71] [78]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Propafenone. Ventricular tachyarrhythmia [BC71] [78]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Flecainide. Ventricular tachyarrhythmia [BC71] [78]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Pentamidine and Amiodarone. Ventricular tachyarrhythmia [BC71] [78]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Pentamidine and Ganciclovir. Virus infection [1A24-1D9Z] [82]
Valganciclovir DMS2IUH Moderate Increased risk of nephrotoxicity by the combination of Pentamidine and Valganciclovir. Virus infection [1A24-1D9Z] [82]
⏷ Show the Full List of 152 DDI Information of This Drug

References

1 Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96.
8 Bis(5-amidino-2-benzimidazolyl)methane and related amidines are potent, reversible inhibitors of mast cell tryptases. J Pharmacol Exp Ther. 1993 Feb;264(2):676-82.
9 Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos. 2009 Feb;37(2):424-30.
10 Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
11 Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. Clin Transplant. 2011 May-Jun;25(3):E271-5.
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
22 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
23 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
24 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
25 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
26 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
27 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
28 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
29 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
30 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
31 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
32 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
33 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
34 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
35 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
36 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
37 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
38 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
39 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
40 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
41 Drug Interactions Flockhart Table
42 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
43 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
44 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
45 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
46 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
47 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
48 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
49 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
50 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
51 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
52 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
53 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
54 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
55 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
56 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
57 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
58 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
59 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
60 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
61 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
62 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
63 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
64 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
65 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
66 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
67 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
68 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
69 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
70 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
71 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
72 Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Pharmacol Ther. 2002 Mar;16(3):407-13.
73 Bayer AG to Develop Arris Asthma Compound; Arris to Receive Milestone Payment. 1996 Business Wire
74 Bayer AG to Develop Arris Asthma Compound; Arris to Receive Milestone Payment. 1996 Business Wire
75 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
76 Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3229-33.
77 Tryptase inhibition blocks airway inflammation in a mouse asthma model. J Immunol. 2002 Feb 15;168(4):1992-2000.
78 Canadian Pharmacists Association.
79 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
80 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
81 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
82 Cerner Multum, Inc. "Australian Product Information.".
83 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
84 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
85 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
86 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
87 FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
88 Chang JT, Green L, Beitz J "Renal failure with the use of zoledronic acid." N Engl J Med 349 (2003): 1676-9 discussion 1676-9. [PMID: 14573746]
89 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
90 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
91 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
92 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
93 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
94 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
95 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
96 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
97 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
98 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
99 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
100 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
101 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
102 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
103 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
104 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
105 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
106 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
107 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
108 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
109 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
110 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
111 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
112 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
113 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
114 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
115 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
116 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]